

IGHD Antibody (N-term)

Mouse Monoclonal Antibody (Mab)

Catalog # AM2141b

Product Information

Application	WB, E
Primary Accession	P01880
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	IgM
Clone Names	607CT8.4.4
Calculated MW	47500
Antigen Region	37-64

Additional Information

Other Names	Ig delta chain C region, IGHG
Target/Specificity	This IGHG antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 37-64 amino acids from the N-terminal region of human IGHG.
Dilution	WB~~1:2000 E~~Use at an assay dependent concentration.
Format	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	IGHG Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	IGHG {ECO:0000303 PubMed:11340299, ECO:0000303 Ref.15}
Function	Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins- secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which

results in the elimination of bound antigens (PubMed:[20176268](#), PubMed:[22158414](#)). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:[17576170](#), PubMed:[20176268](#)). IgD is the major antigen receptor isotype on the surface of most peripheral B-cells, where it is coexpressed with IgM. The membrane- bound IgD (mIgD) induces the phosphorylation of CD79A and CD79B by the Src family of protein tyrosine kinases. Soluble IgD (sIgD) concentration in serum below those of IgG, IgA, and IgM but much higher than that of IgE. IgM and IgD molecules present on B cells have identical V regions and antigen-binding sites. After the antigen binds to the B-cell receptor, the secreted form sIgD is shut off. IgD is a potent inducer of TNF, IL1B, and IL1RN. IgD also induces release of IL6, IL10, and LIF from peripheral blood mononuclear cells. Monocytes seem to be the main producers of cytokines in vitro in the presence of IgD (PubMed:[10702483](#), PubMed:[11282392](#), PubMed:[8774350](#)).


Cellular Location

[Isoform 1]: Secreted

Background

IgD is the major antigen receptor isotype on the surface of most peripheral B-cells, where it is coexpressed with IgM. The membrane-bound IgD (mIgD) induces the phosphorylation of CD79A and CD79B by the Src family of protein tyrosine kinases. Soluble IgD (sIgD) concentration in serum below those of IgG, IgA, and IgM but much higher than that of IgE. IgM and IgD molecules present on B cells have identical V regions and antigen-binding sites. After the antigen binds to the B-cell receptor, the secreted form sIgD is shut off. IgD is a potent inducer of TNF, IL1B, and IL1RN. IgD also induces release of IL6, IL10, and LIF from peripheral blood mononuclear cells. Monocytes seem to be the main producers of cytokines in vitro in the presence of IgD.

Images



IGHD Antibody (N-term)(Cat. #AM2141b) western blot analysis in CEM cell line lysates (35µg/lane). This demonstrates the IGHD antibody detected the IGHD protein (arrow).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.